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PD-L1 enhances CNS inflammation and infarct
volume following experimental stroke in mice in
opposition to PD-1
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Abstract
Background: Stroke severity is worsened by recruitment of inflammatory immune cells into the brain. This process
depends in part on T cell activation, in which the B7 family of co-stimulatory molecules plays a pivotal role.
Previous studies demonstrated more severe infarcts in mice lacking programmed death-1 (PD-1), a member of the
B7 family, thus implicating PD-1 as a key factor in limiting stroke severity. The purpose of this study was to
determine if this protective effect of PD-1 involves either of its ligands, PD-L1 or PD-L2.
Methods: Central nervous system (CNS) inflammation and infarct volume were evaluated in male PD-L1 and PD-L2
knockout (-/-) mice undergoing 60 minutes of middle cerebral artery occlusion (MCAO) followed by 96 hours of
reperfusion and compared to wild-type (WT) C57BL/6J mice.
Results: PD-L1-/- and PD-L2-/- mice had smaller total infarct volumes compared to WT mice. The PD-L1-/- and to a
lesser extent PD-L2-/- mice had reduced levels of proinflammatory activated microglia and/or infiltrating monocytes
and CD4+ T cells in the ischemic hemispheres. There was a reduction in ischemia-related splenic atrophy
accompanied by lower activation status of splenic T cells and monocytes in the absence of PD-L1, suggesting a
pathogenic rather than a regulatory role for both PD-1 ligands (PD-Ls). Suppressor T cells (IL-10-producing CD8
+CD122+ T cells) trafficked to the brain in PD-L1-/- mice and there was decreased expression of CD80 on splenic
antigen-presenting cells (APCs) as compared to the WT and PD-L2-/- mice.
Conclusions: Our novel observations are the first to implicate PD-L1 involvement in worsening outcome of
experimental stroke. The presence of suppressor T cells in the right MCAO-inflicted hemisphere in mice lacking PD-
L1 implicates these cells as possible key contributors for controlling adverse effects of ischemia. Increased
expression of CD80 on APCs in WT and PD-L2-/- mice suggests an overriding interaction leading to T cell activation.
Conversely, low CD80 expression by APCs, along with increased PD-1 and PD-L2 expression in PD-L1-/- mice
suggests alternative T cell signaling pathways, leading to a suppressor phenotype. These results suggest that agents
(for example antibodies) that can target and neutralize PD-L1/2 may have therapeutic potential for treatment of
human stroke.
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Background
Stroke is the fourth most common cause of death and a
leading cause of disability in the United States alone. It
is increasingly accepted that human stroke does not just
create a single organ injury but induces a complex inter-
action between the central nervous system (CNS) and
peripheral immune system. Experimental stroke in mice
induces a biphasic response in the peripheral immune
system characterized by an initial activation phase (6 to
22 hours) [1] followed by an immunosuppressive phase
(96 hours) which is accompanied by a pronounced atro-
phy of the spleen and thymus [2]. Peripheral immune
cells home to the brain, transmigrate over the activated
endothelium and invade the damaged brain in a timed
fashion [3]. The developing infarct is exacerbated by the
influx of inflammatory cells and the time course and de-
gree of accumulation of multiple inflammatory cell types
in the brain has been extensively studied [4-6]. T cells
may be major offenders in mediating the post-stroke in-
flammatory response, contributing to increased brain
damage. When activated, T cells produce cytokines that
initiate an inflammatory cascade involving recruitment
of other inflammatory cells to sites of injury [7]. T cells
are observed in the brain within hours of the ischemic
insult [4,8] and T cell-deficient animals have reduced in-
farct size after stroke [9].
The activation of T cells via the various antigen-
presenting cells (APCs) forms an integral part of the
inflammatory process. This process gains importance es-
pecially since the inflammatory cells in ischemic stroke
include CD4+ and CD8+ T lymphocytes, microglia, and
macrophages [4]. T cell activation is a complex and
multistep phenomenon and the B7 family of co-
stimulatory molecules play a pivotal role in optimal acti-
vation of T cells [10]. Programmed death-1 (PD-1), a
member of the B7-CD28 family, is a co-inhibitory recep-
tor expressed by a variety of activated immune cells, in-
cluding CD4+ and CD8+ T cells, natural killer T (NKT)
cells, B cells, monocytes, and some dendritic cell (DC)
subsets [11]. PD-L1 and PD-L2 are the two known li-
gands for PD-1 [12] and they have different expression
patterns. While PD-L1 is found constitutively expressed
on murine lymphoid cells, such as T cells, B cells, mac-
rophages, DCs, mesenchymal stem cells, and bone
marrow-derived mast cells [13], it is also expressed by
non-hematopoietic cells [12,14-18]. Expression of PD-L2
on the other hand is restricted to macrophages, DCs,
bone marrow-derived mast cells, and peritoneal B1 cells
[12,13,19-21].
Our previous work demonstrated an increased expres-
sion of PD-1 on brain macrophages and microglial cells
and PD-L1/2 on B cells from the spleen, blood, and
CNS in mice after induction of experimental stroke by
middle cerebral artery occlusion (MCAO). Thus, when
MCAO was compared in PD-1 knockout (-/-) versus
wild-type (WT) male mice after 96 hours of reperfusion,
cortical, striatal, and total infarct volumes were signifi-
cantly larger in PD-1-/- versus WT with substantial re-
cruitment of inflammatory cells from the periphery into
the CNS [22], clearly implicating the role of the PD-1
/PD-1 ligand (PD-L) pathway in limiting infarct volume
in MCAO. Thus, the aim of the present study was to ex-
tend our previous studies and investigate the role of the
PD-Ls, PD-L1 and PD-L2, in modulating severity of is-
chemic brain injury and associated CNS inflammation.
For this purpose, PD-L1-/- and PD-L2-/- male mice, on a
C57BL/6 background, were subjected to 60 minutes of
MCAO followed by 96 hours of reperfusion and infarct
volumes and immunological parameters were compared
to similarly treated WT mice. Our results clearly demon-
strate that PD-L1-/- and PD-L2-/- mice had lower total in-
farct volumes compared to WT mice. The immune
parameters matched the stroke outcome in that the PD-
L1-/- and to a lesser extent PD-L2-/- had reduced levels of
proinflammatory activated microglia and/or infiltrating
monocytes and CD4+ T cells in the ischemic hemispheres.
There was a reduction in ischemia-related splenic atrophy
accompanied by lower activation status of splenic T cells
and monocytes in the absence of the PD-L1, suggesting a
pathogenic rather than a regulatory role for both PD-Ls.
Also, suppressor T cells (IL-10-producing CD8+CD122+ T
cells) trafficked to the brain in PD-L1-/- mice possibly
acting as key contributors of immunoregulation. Thus,
these results clearly establish a role for PD-L1 and to a
lesser extent PD-L2 in increasing infarct volumes in ex-




PD-L1-deficient (PD-L1-/-) and PD-L2-deficient (PD-L2-/-)
mice on a C57BL/6 background were gifts from Indira
Guleria, PhD (Transplantation Research Center, Brigham
and Women’s Hospital, Children’s Hospital Boston, and
Harvard Medical School, Boston, MA, USA) and Arlene
Sharpe, PhD (Department of Pathology, Harvard Medical
School, Boston, MA, USA), respectively. Based on Dr.
Guleria’s and Sharpe’s recommendations and previous
publications [20,23], age-matched 8 to 12-week-old male
WT C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME,
USA) were used as controls. Animals were randomized to
treatment groups. All experiments were performed in
accordance with National Institutes of Health (NIH)
guidelines for the use of experimental animals, and the
protocols were approved by Portland Veteran Affairs
Medical Center and Oregon Health & Science University
Animal Care and Use Committees.
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Middle cerebral artery occlusion (MCAO) model
All surgeries were conducted under aseptic conditions
by a single surgeon who was not blinded to the animal’s
genotype. Transient focal cerebral ischemia was induced
in male PD-L1-/-, PD-L2-/-, and WT mice for 60 minutes
by reversible right MCAO under isoflurane anesthesia
followed by 96 hours of reperfusion as previously
described [24]. Head and body temperature were con-
trolled at 36.5 ± 1.0°C (mean ± SD) before, during, and
after MCAO with warm water pads and a heating lamp.
The common carotid artery was temporarily occluded
and a 6-0 nylon monofilament surgical suture (Ethicon,
Somerville, NJ, USA) with a silicone-coated (Xantopren
Comfort Light, Heraeus, Hanau, Germany) tip was
inserted via an external carotid artery stump distal to
the internal carotid artery to the origin of the middle
cerebral artery. After 60 minutes of MCAO, reperfusion
was initiated by intraluminal filament withdrawal and
the incision was closed with 6-0 surgical sutures
(Ethicon). Each animal was then awakened and recov-
ered in a separate cage with a warm water pad. In sham-
treated mice, the filament was placed but not advanced
to achieve MCAO. Occlusion and reperfusion were veri-
fied in each animal by laser Doppler flowmetry (LDF)
(Model DRT4, Moor Instruments, Wilmington, DE,
USA). Animals were excluded if intraischemic LDF (per-
centage of preischemic LDF baseline) was greater than
30%. Neurological deficit scores were determined at 1,
24, 48, 72, and 96 hours of reperfusion to confirm is-
chemia and the presence of ischemic injury using a 0
to 4-point scale as follows: 0, no neurological dys-
function; 1, failure to extend left forelimb fully when
lifted by tail; 2, circling to the contralateral side; 3,
falling to the left; and 4, no spontaneous movement
or in a comatose state [24]. Any animal without a
deficit at 1 hour of reperfusion was excluded from
the study.
Infarct volume analysis
Individual performing infarct volume analysis was
not blinded to genotype. Mice were euthanized and
brains collected at 96 hours of reperfusion for 2,3,5-
triphenyltetrazolium chloride histology and then digital
image analysis of infarct volume was undertaken as
previously published [24]. Images were analyzed using
SigmaScan Pro 5.0 (Systat Software, Inc, Point Richmond,
CA, USA). To control for edema, regional infarct volume
(cortex, striatum, and hemisphere) was determined by
subtraction of the ipsilateral non-infarcted regional vol-
ume from the contralateral regional volume. This value
was then divided by the contralateral regional volume and
multiplied by 100 to yield regional infarct volume as a per-
centage of the contralateral region.
Cell isolation
Splenocyte suspensions were prepared by mechanical
disruption followed by using red cell lysis buffer
(eBioscience, San Diego, CA, USA) according to the
manufacturer’s instructions. For preparation of inflam-
matory cells from the brain, each mouse was perfused
transcardially with 30 mL saline to exclude blood cells,
the forebrain was dissected from the cerebellum and
suspended in RPMI-1640 medium, and the suspension
was digested with type IV collagenase (1 mg/mL, Sigma-
Aldrich, St Louis, MO, USA) and DNase I (50 mg/mL,
Roche, Basel, Switzerland) at 37°C for 45 minutes in a
shaker at 180 times per minute. Inflammatory cells were
isolated by 37% to 70% Percoll density gradient centrifuga-
tion as previously described [25]. The cells were washed
twice with RPMI-1640, counted, and resuspended in
stimulation medium containing 10% FCS for phenotyping.
Analysis of cell populations by FACS
Individual performing FACS analysis was not blinded to
genotype. Anti-mouse antibodies CD19 (1D3, BD
Pharmingen, BD, Franklin Lakes, NJ, USA), CD45 (30-
F11, Invitrogen, Carlsbad, CA, USA), CD11b (M1/70,
eBioscience), MHCII (2G9, BD Pharmingen, BD), CD4
(GK1.5, BD Pharmingen, BD), CD8 (53-6.7, BD
Pharmingen, BD), CD69 (H1.2F3, BD Pharmingen, BD),
CD122 (TM-β1, BD Pharmingen, BD), PD-1 (RMP1-30,
eBioscience), PD-L1 (MIH5, eBioscience), and PD-L2
(TY25, eBioscience) were used for the study. Single-cell
suspensions were washed with staining medium (PBS
containing 0.1% NaN3 and 2% FCS). After incubation
with mAb and washing with staining buffer, propidium
iodide (PI) was added to identify dead cells. The Foxp3
staining kit (eBioscience) was used according to the
manufacturer’s protocol as previously described [26].
FACS data acquisition was performed on a FACSCalibur
flow cytometer (BD Biosciences, San Jose, CA, USA)
and data were analyzed using isotype control antibodies
to set quadrants before calculating the percentage of
positive cells, using FCS Express (De Novo Software, Los
Angeles, CA, USA).
Intracellular staining
Intracellular staining was visualized using a published
immunofluorescence protocol [27]. Briefly, 2 × 106 cells/
mL were resuspended in complete medium (RPMI-1640
containing 10% FCS, 1 mM/L pyruvate, 200 μg/mL peni-
cillin, 200 U/mL streptomycin, 4 mM/L L-glutamine, and
5 × 10−5 mol/L 2-β-ME), with PMA (50 ng/mL),
ionomycin (500 ng/mL), and Brefeldin A (10 μg/mL,
Sigma-Aldrich) for 4 hours. For intracellular IL-10
detection, a modification was followed for the immuno-
fluorescence staining protocol [28]. Briefly, isolated leuko-
cytes or purified cells were resuspended (2 × 106 cells/mL)
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in complete medium and cultured with LPS (10 μg/mL) in
addition to PMA (50 ng/mL), ionomycin (500 ng/mL),
and Brefeldin A (10 μg/mL) (all reagents from Sigma-
Aldrich) for 4 hours. Fc receptors were blocked with anti-
FcRmAb (2.3G2, BD Pharmingen, BD) before cell surface
staining, fixed, and permeabilized with the Fixation/
Permeabilization buffer (eBioscience) according to the
manufacturer’s instructions. Permeabilized cells were
washed with 1X Permeabilization Buffer (eBioscience) and
stained with anti-TNF-α (MP6-XT22, BD Pharmingen,
BD), anti-INF-γ (XMG1.2, eBioscience), or APC-
conjugated anti-IL-10 mAb (JES5-16E3, eBioscience).
Isotype matched mAb served as negative controls to dem-
onstrate specificity and to establish background TNF-α,
IFN-γ, and IL-10 staining levels.
Statistical analysis
Infarct volume data are presented as mean ± SEM. Dif-
ferences in cortical, striatal, and hemispheric (total)
infarct volume were determined by one-way analysis of
variance (ANOVA) with post-hoc Newman-Keuls test. A
Kruskal-Wallis ANOVA on ranks was conducted to
evaluate differences among the three experimental
groups (WT, PD-L1-/-, and PD-L2-/-) in median
neurological deficit score. Post-hoc Dunn’s test was
used for all pairwise comparisons against the control
(WT) group following rank-based ANOVA as treat-
ment group sizes were unequal. The multiple com-
parisons on ranks did not include an adjustment for
ties. Statistical significance was P <0.05. Statistical
analyses were performed using SigmaStat Statistical
Software, Version 3.1 (SPSS Inc, Chicago, IL, USA).
For flow data analysis and representation of three
and more groups, the one-way ANOVA followed by
post-hoc Tukey’s test was applied. For all tests, P
values ≤0.05 were considered statistically significant. All
values are reported as mean ± SEM. Significant differences
are denoted as *P ≤0.05; **P ≤0.01; ***P ≤0.001.
Results
Absence of PD-1 ligands ameliorates infarct volume and
reduces neurological deficits
Genetic deletion of either PD-L1 (25 ± 4%, P <0.001) or
PD-L2 (32 ± 5%, P = 0.006) reduced cortical infarct
volume when compared to male WT mice (50 ± 3%)
(Figure 1A). In striatum, genetic deletion of PD-L1 (41 ±
8%, P = 0.024), but not PD-L2 (62 ± 5%, P = 0.502), de-
creased infarct volume in comparison to male WT mice
(69 ± 8%) (Figure 1A). While no differences were seen in
cortical infarct volume between PD-L1-/- and PD-L2-/-
mice (P = 0.214), striatal infarct volume did differ
between these two strains (P = 0.040) (Figure 1A).
Compared to male WT mice (51 ± 3%), genetic dele-
tion of either PD-L1 (20 ± 4%, P <0.001) or PD-L2
(35 ± 4%, P = 0.005) reduced hemispheric infarct vol-
ume. We also observed that hemispheric infarct volume
was smaller in PD-L1-/- versus PD-L2-/- mice (20 ± 5%
versus 35 ± 4%, P = 0.006). Representative cerebral sec-
tions from WT, PD-L1-/-, and PD-L2-/- mice are shown in
Figure 1B.
Distribution of neurological deficit scores within each
group at each time point would suggest that loss of PD-
L1 had a greater impact on decreasing, and thus improv-
ing, neurological deficit score over time than did loss of
PD-L2 when compared to WT mice (Table 1). Differ-
ences in the median neurological deficit scores among
the three experimental groups (WT, PD-L1-/-, and PD-
L2-/-) were greater than would be expected by chance at
Figure 1 Absence of PD-1 ligands reduces infarct volume. Infarct volume (percentage corrected contralateral structure) in cortex, striatum,
and hemisphere were determined by 2,3,5-triphenyltetrazolium chloride staining in adult male C57BL/6J wild-type (WT), PD-L1-/-, and PD-L2-/-
mice. All mice underwent 1 hour of middle cerebral artery occlusion (MCAO) followed by 96 hours of reperfusion. (A) PD-L1-/- (n = 12) and
PD-L2-/- (n = 12) mice have reduced infarct volume compared to male WT mice (n = 11). Values represent mean ± SEM. *P <0.05; **P <0.01.
(B) Representative cerebral sections showing that localization of the ischemic lesion differed among WT, PD-L1-/-, and PD-L2-/- mice. -/-, knockout;
MCAO, middle cerebral artery occlusion; PD-1, programmed death-1; PD-L1, programmed death-1 ligand 1; PD-L2, programmed death-1 ligand 2;
SEM, standard error of the mean; WT, wild-type.
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1 hour (P = 0.013), 24 hours (P = 0.044), 48 hours (P =
0.031), and 96 hours (P = 0.020) of reperfusion, but not
at 72 hours of reperfusion (P = 0.062) (Table 1). A sig-
nificant difference (P <0.05) was observed between WT
and PD-L1-/- groups at 1 hour and 24 hours of reperfu-
sion (Table 1). Thus, these results demonstrate for the
first time that although PD-1 limits the damage after
MCAO, its ligands PD-L1 and PD-L2 enhance infarct
volumes.
Absence of PD-L1 leads to reduced cerebral cell
infiltration and inflammatory responses in the ischemic
brain
Leukocytes are major effectors of inflammatory damage
after experimental brain ischemia. To determine if the
loss of the PD-Ls altered leukocyte composition in the
brain after MCAO, absolute numbers of total viable
leukocytes were enumerated. The ischemic (ipsilateral)
hemisphere in the WT mice had a significant increase
(P ≤0.001) in the total number of viable leukocytes as
compared to the unaffected (contralateral) hemisphere
(Figure 2A). While the PD-L2-/- mice also demonstrated
significantly higher numbers (P ≤0.05) of leukocytes in
their ipsilateral hemispheres compared to the contralateral
side, there was no difference in the numbers of viable
leukocytes between the ipsilateral and contralateral
hemispheres of PD-L1-/- mice. The PD-L1-/- mice demon-
strated significantly lower cell infiltration in the ischemic
hemisphere as compared to WT mice (P ≤0.05). However,
there was no difference in leukocyte numbers between the
ischemic brains of the PD-L1-/- and PD-L2-/- mice
(Figure 2A).
Since PD-L1-/- mice demonstrated significantly less se-
vere clinical and histological signs of MCAO after 96
hours of reperfusion, we evaluated the immune cell traf-
ficking into the CNS of these mice compared to WT and
PD-L2-/- mice. Mononuclear cells, isolated from ischemic
and non-ischemic hemispheres of brains of WT, PD-L1-/-,
and PD-L2-/- mice after 96 hours of reperfusion, were
stained for several cell surface markers. Upon characteriz-
ing infiltrating mononuclear cells in the brains, it was re-
vealed that ischemic brain hemispheres of WT (P ≤0.001)
and PD-L2-/- mice (P ≤0.05) had significantly higher
numbers of microglia and/or infiltrating monocytes/mac-
rophages as compared to their respective non-ischemic
halves, while there was no increase in these cells in the
ischemic brains of the PD-L1-/- mice. The ischemic hemi-
spheres of the PD-L1-/- mice, in fact, had significantly
lower numbers of CD11b+CD45high population as
compared to the ischemic halves of WT (P ≤0.001) and
PD-L2-/- (P ≤0.05) mice (Figure 2B). Similarly, although
there was a significant increase in the numbers of CD4+ T
cells in the ischemic hemispheres of WT (P ≤0.001) and
PDL2-/- mice (P ≤0.01) as compared to their non-ischemic
halves, there were no differences in the PD-L1-/- mice
post-MCAO. The ischemic hemispheres of the PD-L1-/-
had significantly lower CD4+ T cells (P ≤0.05) as com-
pared to WT mice (Figure 2C). Both of these populations
have been known to accumulate by day 3 postischemic
brain injury leading to subsequent production of
proinflammatory cytokines and upregulation of cell adhe-
sion molecules [4]. However, when the total CD8+ T
cell population was analyzed in the brain, we ob-
served a significant increase of CD8+ T cell numbers
not only in the right hemispheres of the PD-L1-/-
mice (P ≤0.05) as compared to both WT and PD-L2-/-
mice, but also significantly more (P ≤0.05) in the left
hemisphere of the PD-L1-/- mice as compared to the
PD-L2-/- mice post-MCAO (Figure 2D). Thus, with
lower infarct volumes, infiltration of inflammatory cells
into the CNS was also abrogated in the absence of PD-L1,
whereas they were retained in the absence of PD-L2.
Furthermore, TNF-α production by CD11b+CD45high
subpopulation (Figure 2E) and CD3+ T cells (Figure 2F)
Table 1 Neurological deficit score distribution and median scores at various reperfusion time points following 60
minutes of middle cerebral artery occlusion (MCAO) in wild-type (WT, C57BL/6J), PD-L1-/-, and PD-L2-/- mice
Experimental
groups
Distribution of neurological deficit scores post-MCAO
1 hour 24 hours 48 hours 72 hours 96 hours
0 1 2 3 4 0 1 2 3 4 0 1 2 3 4 0 1 2 3 4 0 1 2 3 4
WT (n = 11) 0 0 4 7 0 0 4 1 6 0 0 5 3 6 0 0 5 5 1 0 0 5 2 4 0
PD-L1-/- (n = 12) 0 1 10 1 0 0 9 2 1 0 0 11 0 1 0 0 11 1 0 0 0 12 0 0 0
PD-L2-/- (n = 12) 0 0 6 6 0 0 3 8 1 0 0 4 8 0 0 0 7 2 3 0 0 7 1 1 3
Median neurological deficit scores post-MCAO
1 hour (P = 0.013) 24 hours (P = 0.044) 48 hours (P = 0.031) 72 hours (P = 0.062) 96 hours (P = 0.020)
WT (n = 11) 3 3 2 2 2
PD-L1-/- (n = 12) 2a 1a 1 1 1
PD-L2-/- (n = 12) 2.5 2 2 1 1
aP <0.05 compared to WT. -/-, knockout; MCAO, middle cerebral artery occlusion; PD-L1, programmed death-1 ligand 1; PD-L2, programmed death-1 ligand 2;
WT, wild-type.
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was determined. The TNF-α production was significantly
higher in the T cells of ischemic hemisphere of the
brains of WT mice compared to its contralateral hemi-
sphere (P <0.01) and also as compared to the ischemic
hemisphere of PD-L1-/- mice (P <0.05). The ischemic
hemispheres of the PD-L2-/- mice also had a significantly
higher percentage of TNF-α-producing CD3+ T cells as
compared to its contralateral side (P ≤0.05) and as com-
pared to the ischemic hemisphere of PD-L1-/- mice (P
≤0.01) (Figure 2E), further confirming the reduction in
inflammatory milieu in the absence of PD-L1.
Absence of PD-L1 rescues MCAO-induced splenic atrophy
and inhibits activation states of splenic T cells and
monocytes
In lieu of the unexpected decreased infarct volumes in
the PD-L1-/- and PD-L2-/- mice, the peripheral immune
status was assessed in sham-treated WT, PD-L1-/-, and
PD-L2-/- mice to ascertain if there were any existing
differences in immune parameters before MCAO that
could affect infarct volume following MCAO. Sham
MCAO surgeries were performed in each mouse strain
by placing the intraluminal filament but not advancing it
to achieve MCAO. However, as illustrated in Tables 2A
and 3A, no significant differences either in absolute
numbers of splenocytes or any of the immune parame-
ters analyzed were observed. Since our laboratory has
previously established a stroke-induced splenic atrophy
phenomenon [2], splenic cell numbers in each of the
WT, PD-L1-/-, and PD-L2-/- mice were evaluated at 96
hours post-MCAO. As expected and previously demon-
strated [2], MCAO resulted in large reductions in spleen
cell numbers in WT mice. The reduction in spleen
counts was from approximately 80 million spleen cells/
sham WT mouse (data in Table 2A) to approximately 9
million spleens cells/WT mouse after 60 minutes of
MCAO and 96 hours of reperfusion, accounting for ap-
proximately 89% reduction in the total splenocytes
Figure 2 Absence of PD-L1 reduces cerebral cell infiltration and inflammatory responses in the ischemic brain. Ninety-six hours after
MCAO, mononuclear cells were isolated from the brains of WT, PD-L1-/-, and PD-L2-/- male mice and analyzed. (A) Total cell count via
hemocytometer. Values represent mean numbers (± SEM) of indicated cell subsets from 9 to 11 mice per group, from three separate
experiments. (B) CD11b+CD45high activated microglia/monocytes. (C) CD4+ T cells and (D) CD8+ T cells were obtained from the non-ischemic
(left) and ischemic (right) hemispheres of WT, PD-L1-/-, and PD-L2-/- mice. (B,C,D) Values represent mean numbers (± SEM) of indicated cell
subsets, gated on live leukocytes (by PI exclusion) from eight to nine mice per group, from at least three separate experiments. Determinations of
(E) TNF-α production by CD11b+CD45high activated microglia/monocytes and (F) TNF-α+CD3+ T cells in the non-ischemic (left) and ischemic
(right) hemispheres from WT, PD-L1-/-, and PD-L2-/- mice at 96 hours post-MCAO. Values represent mean numbers (± SEM) of indicated cell
subsets from four to five mice of each group, from at least two separate experiments. Statistical analysis was performed with ANOVA followed by
Tukey’s multiple comparison post-hoc test. Significant differences between sample means are indicated (#P ≤0.05; ##P ≤0.01; ###P ≤0.001 as
compared to their respective left hemisphere and *P ≤0.05; **P ≤0.01 as compared to the ischemic right hemisphere of PD-L1-/- mice
post-MCAO). -/-, knockout; ANOVA, analysis of variance; MCAO, middle cerebral artery occlusion; PD-L1, programmed death-1 ligand 1; PD-L2,
programmed death-1 ligand 2; PI, propidium iodide; SEM, standard error of the mean; TNF, tumor necrosis factor; WT, wild-type.
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(Table 2B). Interestingly, the spleens of PD-L1-/- mice
did not sustain such marked atrophy in the splenic num-
bers (accounting for approximately 73% reduction as
compared to its sham-treated group) (Table 2B). These
viable cell counts in MCAO-induced PD-L1-/- mice were
significantly higher than those of the MCAO-induced
WT mice (P <0.05). While the spleens of PD-L2-/-
underwent an approximately 80% reduction from their
sham state, this change was not significant when com-
pared to the viable splenic cell numbers from either
MCAO-induced WT or PD-L1-/- mice (Table 2B).
Given the partial restoration of splenic cell numbers in
the MCAO-induced PD-L1-/- and PD-L2-/- mice, we fur-
ther evaluated specific surviving splenic cell types. Per-
centages of T cells (CD4+ T cells and CD8+ T cells), B
cells, and monocytes were enumerated. As previously
determined [2], the WT mice post-MCAO demonstrated
an increase in the percentages of CD4+ T cells and CD8+
T cells, with a reduction in the B cell percentages
(Table 3B). Similarly, there was a significant increase in
the percentage of T cells (CD4+ and CD8+) in both the
MCAO-induced PD-L1-/-, and in the MCAO-induced
PD-L2-/- as compared to their sham-treated counterparts
(Table 3A,B). Moreover the percentages of T cells (CD4+
and CD8+) in the spleens of MCAO-induced PD-L1-/-
mice were significantly higher than those in the MCAO-
subjected WT, with no significant difference between the
WT and PD-L2-/- cell composition (Table 3B). The PD-L
knockout strains had a substantial loss of B cell percent-
ages from their spleens not only when compared to their
sham counterparts but also with the MCAO-induced WT
mice. No differences in the percentage of monocytes were
determined between strains or within treatment condi-
tions (Table 3A,B). However, in spite of these changes
in percentages, there remained higher absolute num-
bers of T cells, B cells, and monocytes in the PD-L1-/-
and PD-L2-/- mice with MCAO compared to WT mice
(data calculated from Tables 2 and 3), indicating rela-
tive preservation of all cell types in PD-L-deficient
mice.
At this point, it was unclear whether increased accu-
mulation of CD4+ and CD8+ T cells in PD-L1-/- mice
was due to decreased apoptosis or increased prolifera-
tion of T cells. To further ascertain, splenocytes were
evaluated for the expression of PI, with PI+ cells indi-
cating dying splenocytes. As indicated in Table 4, the
PD-L1-/- mice had a significant reduction in the per-
centage of PI+ cells at 96 hours after reperfusion as
compared to the MCAO-induced WT mice. The
MCAO-subjected PD-L1-/- mice also demonstrated
more T cell proliferative responses as compared to
the WT mice, whereas the T cell proliferative re-
sponses of the PD-L2-/- mice were comparable to
those of the MCAO-induced WT mice (data not
shown). Thus, these results clearly demonstrate that
the presence of PD-L1 contributes more to MCAO-
induced cell death and less proliferative responses
than PD-L2 after 96 hours of ischemic stroke in
mice.
To further evaluate the possible differences due to
the loss of the PD-Ls that could have led to attenu-
ated stroke outcome, activation states of T cells and
monocytes were quantified in mice subjected to 60
minutes of MCAO and 96 hours of reperfusion. Thus,
Table 2 Spleen cell yield from sham and MCAO-subjected WT, PD-L1-/-, and PD-L2-/- mice
A B
Cell yield (× 106) Cell yield (× 106)
WT PD-L1-/- PD-L2-/- WT PD-L1-/- PD-L2-/-
Sham (n) Sham (n) Sham (n) MCAO (n) MCAO (n) MCAO (n)
79.9 ± 4.5 (9) 85.6 ± 3.1 (13) 94.3 ± 3.6 (10) 8.9 ± 7.3 (12)a,b 23.1 ± 3.5 (19)a 19.5 ± 1.9 (14)a
Data are presented as mean ± SEM. aValue of P ≤0.05 with respect to the strain’s sham group; bvalue of P ≤0.05 versus MCAO-induced PD-L1-/- mice. -/-, knockout;
MCAO, middle cerebral artery occlusion; PD-L1, programmed death-1 ligand 1; PD-L2, programmed death-1 ligand 2; WT, wild-type.
Table 3 Percentage of different cell types in spleens of WT, PD-L1-/-, and PD-L2-/- male mice 96 hours after MCAO
A B
Cell types (%) Cell types (%)
Cell type WT PD-L1-/- PD-L2-/- Cell type WT PD-L1-/- PD-L2-/-
Sham (n) Sham (n) Sham (n) MCAO (n) MCAO (n) MCAO (n)
CD4 20.7 ± 3.9 (7) 21.5 ± 2.5 (9) 17.7 ± 3.1 (8) CD4 25.4 ± 4.2 (8)b 32.8 ± 6.2 (9)a 25.0 ± 6.5 (7)a,b
CD8 8.9 ± 3.1 (7) 11.4 ± 2.3 (9) 9.4 ± 2.3 (8) CD8 13.9 ± 6.0 (8)b 25.0 ± 8.3 (9)a 21.3 ± 5.4 (7)a
CD19 64.8 ± 7.3 (7) 60.0 ± 4.0 (9) 65.5 ± 2.9 (8) CD19 53.7 ± 9.0 (8)b 40.3 ± 7.7 (11)a 43.2 ± 12.5 (7)a
CD11b 2.3 ± 0.9 (7) 4.4 ± 1.8 (9) 3.3 ± 0.6 (8) CD11b 2.0 ± 0.7 (9) 3.2 ± 2.1 (9) 1.9 ± 1.5 (7)
Data are presented as mean ± SEM. aValue of P ≤0.05 with respect to the strain’s sham group; bvalue of P ≤0.05 versus MCAO-induced PD-L1-/- mice. -/-, knockout;
MCAO, middle cerebral artery occlusion; PD-L1, programmed death-1 ligand 1; PD-L2, programmed death-1 ligand 2; WT, wild-type.
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to correlate the reduced infarct volumes and reduced
splenic atrophy to the activation states of T cells in
the spleens which might be influencing the splenic
milieu, we evaluated the percentage expression of
CD69 by CD4+ T cells and CD8+ T cells, and of
major histocompatibility complex (MHC) class II by
CD11b+ monocytes in the spleens of MCAO-induced
WT, PD-L1-/-, and PD-L2-/- mice. CD69 is an ‘activa-
tion marker’ that is rapidly induced on mature T cells
after stimulation through the TCR. As shown in
Figures 3A,B, splenocytes from PD-L1-/- mice after
MCAO had significantly decreased percentages of
CD69+CD4+ (P ≤0.05) and CD69+CD8+ (P ≤0.05) T
cells as compared to the MCAO-induced WT mice.
The activation states of T cells (CD4+ and CD8+) in
the PD-L2-/- mice were slightly reduced as compared
to the WT mice after MCAO, but not significantly.
Similarly, the expression of MHC class II on monocytes
was significantly reduced (P ≤0.05) in the PD-L1-/- mice
(Figure 3C) as compared to those in MCAO-induced
WT mice. These results indicate that PD-L1 and to a
lesser extent PD-L2 facilitates the increased activa-
tion of T cells and monocytes at 96 hours post-
MCAO.
Table 4 Percentage of dead (propidium iodide (PI+)) cells
in spleens of WT, PD-L1-/-, and PD-L2-/- male mice 96
hours after MCAO
Dead cells (PI+ %)
WT PD-L1-/- PD-L2-/-
MCAO (n) MCAO (n) MCAO (n)
24.3 ± 6.4 (12)a 18.3 ± 2.4 (19) 20.2 ± 3.9 (14)
Data are presented as mean ± SEM. aValue of P ≤0.05 versus MCAO-induced
PD-L1-/- mice. -/-, knockout; MCAO, middle cerebral artery occlusion; PD-L1,
programmed death-1 ligand 1; PD-L2, programmed death-1 ligand 2; PI,
propidium iodide; WT, wild-type.
Figure 3 Absence of PD-L1 inhibited activation states of splenic T cells and monocytes post-MCAO. Ninety six hours after MCAO,
mononuclear cells were isolated from spleens of WT, PD-L1-/-, and PD-L2-/- mice and analyzed. (A) Expression of activation marker CD69 on gated
CD4+ T cells. (B) Expression of activation marker CD69 on gated CD8+ T cells. (C) Expression of MHC class II by CD11b+ monocytes. Values
represent mean numbers (± SEM) of indicated cell subsets, gated on live leukocytes (by PI exclusion) from seven to eight mice in each group,
from at least three separate experiments. Statistical analysis was performed with ANOVA followed by Tukey’s multiple comparison post-hoc test.
Significant differences between sample means are indicated. *P ≤0.05 compared to the PD-L1-/- mice post-MCAO. -/-, knockout; ANOVA, analysis
of variance; MCAO, middle cerebral artery occlusion; MHC, major histocompatibility complex; PD-L1, programmed death-1 ligand 1; PD-L2,
programmed death-1 ligand 2; PI, propidium iodide; SEM, standard error of the mean; WT, wild-type.
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Absence of PD-L1 leads to increased expression of PD-1
on T cells with no difference in Foxp3+ T cells in the
spleens
Since our previous work [22] implicated PD-1 signaling
in limiting CNS inflammation in MCAO, we next sought
to assess the expression of this co-inhibitory receptor on
the splenic T cells from each of the three mouse strains
post-MCAO. Interestingly, there was a significant in-
crease in percentage of PD-1 expression on both splenic
CD4+ and CD8+ T cells of the PD-L1-/- mice at 96 hours
post-MCAO (Figure 4A,B). This increase was signifi-
cant as compared to both the WT mice (P ≤0.01) for
CD4+ and CD8+ T cells, and also to the PD-L2-/-
mice (P ≤0.05) for CD4+ T cells and (P ≤0.01) for
CD8+ T cells. However, there were no differences in the
expression of PD-1 among strains of the sham-treated
mice. Our earlier studies demonstrated that MCAO in-
duced a threefold increase in the percentage of Foxp3
+CD4+ Tregs in the spleens as compared to sham or naive
mice [2]. Also, a role for the PD-1/PD-L pathway in gener-
ation of Tregs has been supported by a number of studies
[1,8]. Hence, the levels of Foxp3+CD4+ T cells were
assessed in each of the three mouse strains, post-
MCAO. The PD-L-deficient mice demonstrated a trend
towards lower expression of Foxp3+CD4+ T cells although
these levels were not significant as compared to those in
the WT mice at 96 hours post-MCAO (Figure 4C). These
results still indicate that PD-1 as demonstrated earlier [7]
might play a crucial role through its interaction with an-
other ligand, predominantly PD-L2, in the absence of PD-
L1, leading to decreased activation states of the T cells at
96 hours post-MCAO.
Absence of PD-L1 results in loss of suppressor T cells
from spleens
To further evaluate possible regulatory parameters, we
assessed the expression of a recently characterized regula-
tory T cell (Treg) sub-population known as CD8+CD122+
suppressor T cells [29]. CD8+CD122+ Tregs are naturally
occurring Tregs that effectively suppress the prolifera-
tion and IFN-γ production of both CD8+ and CD4+
target cells by virtue of their IL-10 production [30]. A
significant decrease in the percentage of CD8+CD122+
Tregs in the PD-L1-/- mice both as compared to the
Figure 4 Absence of PD-L1 led to increased expression of PD-1 on T cells with no difference in Foxp3+ T cells in the spleens.
Splenocytes from WT, PD-L1-/-, and PD-L2-/- mice were harvested at 96 hours post-MCAO or sham-treatment and assessed for expression. (A) PD-
1 expression on gated CD4+ T cells. (B) PD-1 expression on gated CD8+ T cells. (C) Expression of Foxp3+CD4+ T cells. Values represent mean
numbers (± SEM) of indicated cell subsets from four to five mice of each group, from two separate experiments. Statistical analysis was
performed with ANOVA followed by Tukey’s multiple comparison post-hoc test. Significant differences between sample means are indicated
(#P ≤0.05 and ###P ≤0.001 as compared to their respective sham;*P ≤0.05 and **P ≤0.01 compared to the PD-L1-/- mice post-MCAO). -/-,
knockout; ANOVA, analysis of variance; MCAO, middle cerebral artery occlusion; PD-1, programmed death-1; PD-L1, programmed death-1 ligand 1;
PD-L2, programmed death-1 ligand 2; SEM, standard error of the mean; WT, wild-type.
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WT (P ≤0.05) and the PD-L2-/- (P ≤0.05) mice is
shown in Figure 5A. Upon trying to rationalize this
decrease in CD8+CD122+ T cells from the spleens,
low infarcts in the PD-L1-/- mice and increased num-
bers of total CD8+ T cells in the ischemic hemi-
spheres of PD-L1-/- mice, we speculated a plausible
exit of these suppressors from the spleens and their
entry into the ischemic hemisphere of the brains.
Upon further characterizing the CD8+ T cells in the
brains for the presence of the suppressor CD8+ T cell
sub-population, there was indeed a significant in-
crease in the percentage of CD8+CD122+ T cells in
the ischemic hemispheres of the PD-L1-/- mice as
compared to those found in the ischemic hemispheres
of the WT mice (P ≤0.05) after 96 hours of reperfu-
sion (Figure 5B). Not only were the percentages of
the suppressor CD8+ T cells higher, but they also
expressed higher IL-10 levels in the ischemic half of
the brains of PD-L1-/- mice. These data strongly sup-
port the contention that in the absence of PD-L1, the
suppressor T cells are able to exit the periphery and
enter the CNS, thereby contributing to a plausible
immunomodulation following stroke and thereby
preventing further damage from pro-inflammatory
factors after the 96-hour timeframe.
Absence of PD-L1 leads to decreased expression of CD80
on APCs in spleens
Recent studies demonstrated that PD-L1 binds CD80
(B7-1) besides PD-1, and PD-L1/CD80 interaction also
delivers inhibitory signals in T cells [31,32]. Hence, in
our attempt to address this mechanistic possibility,
we analyzed CD80 expression on the APCs in the
periphery. As demonstrated in Figure 6A, there was a
significant reduction in CD80 expression on the
CD11c+ DCs in the PD-L1-/- mice, both as compared
to the WT (P ≤0.05) and PD-L2-/- (P ≤0.05) mice,
and by the CD11b+ monocytes (P ≤0.01) (Figure 6B)
and CD19+ B cells (P ≤0.05) (Figure 6C) as compared
to the WT mice post-MCAO. There was no differ-
ence in the CD80 expression on CD11c+, CD11b+,
and CD19+ cells in sham MCAO conditions. The
Figure 5 Absence of PD-L1 resulted in loss of suppressor T cells from spleens. Splenocytes from WT, PD-L1-/-, and PD-L2-/- mice were
harvested at 96 hours post-MCAO and assessed. (A) Expression of CD8+CD122+ T cells. Data are representative of two independent experiments
with spleens processed from four to five individual mice (mean ± SEM). Statistical analysis was performed with ANOVA followed by Tukey’s
multiple comparison post-hoc test. Significant differences between sample means are indicated (*P ≤0.05 compared to the PD-L1-/- mice post-
MCAO). Subsequently, mononuclear cells were isolated from brains of WT, PD-L1-/-, and PD-L2-/- male mice and analyzed. (B) CD8+CD122+ T cells
and IL-10 production by gated CD8+CD122+ T cells. Data are representative of two independent experiments with spleens processed from four
to five individual mice (mean ± SEM). Statistical analysis was performed with ANOVA followed by Tukey’s multiple comparison post-hoc test.
Significant differences between sample means are indicated (#P ≤0.05 as compared to their respective left hemisphere and *P ≤0.05 as
compared to the ischemic right hemisphere of PD-L1-/- mice post-MCAO). -/-, knockout; ANOVA, analysis of variance; MCAO, middle cerebral
artery occlusion; PD-L1, programmed death-1 ligand 1; PD-L2, programmed death-1 ligand 2; SEM, standard error of the mean; WT, wild-type.
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CD80 expressing CD11b+ and CD19+ cells increased
significantly (P ≤0.001) in the WT mice post-MCAO
as compared to the shams. In the PD-L1-/- and PD-L2-/-
mice, CD80 expression on CD11b+ cells (P ≤0.01) and
CD80 expression on CD11c+ cells increased significantly
(P ≤0.001), respectively, post-MCAO, as compared to
their sham-treated counterparts. However, the PD-L1-/-
mice, as demonstrated in Figure 4A, also increased PD-1
expression on the T cells. In light of this finding and the
reduced expression of CD80 on the APCs, we hypothe-
sized that in the absence of PD-L1, PD-L2 being the only
available co-inhibitory ligand for PD-1, the PD-1/PD-L2
interaction might also lead to co-inhibition. Hence, we
determined the total PD-L1 and PD-L2 expression on
leukocytes in sham and MCAO-subjected mice. As dem-
onstrated in Figure 6D, although expression levels of
PD-L1 in the WT mice increased post-MCAO as com-
pared to its sham (P ≤0.05), there was no difference in the
PD-L1 expression between the WT and PD-L2-/- mice
after MCAO, with no difference between the groups in
sham conditions. However, there was indeed an in-
crease in the total PD-L2 expression in the PD-L1-/-
mice as compared to the WT mice (P ≤0.001) post-
MCAO (Figure 6E), making a plausible case for a
PD-1/PD-L2 co-inhibitory interaction.
Discussion
Ischemic stroke induces neurological deficits in almost
one-third of patients, leading to increased mortality and
long-term functional disability [33,34]. Although under-
lying mechanisms have not been completely unraveled,
that ischemia evokes inflammatory responses has been
Figure 6 Absence of PD-L1 led to decreased expression of CD80 on APCs in spleens post-MCAO. Splenocytes from WT, PD-L1-/-, and PD-
L2-/- mice were harvested at 96 hours post-MCAO or sham-treatment and assessed for expression. CD80 expression on gated (A) CD11c+, (B)
CD11b+, and (C) CD19+ cells. (D) Expression of total PD-L1 and (E) PD-L2 on leukocytes. Values represent mean numbers (± SEM) of indicated cell
subsets, gated on live leukocytes (by PI exclusion) from four to five mice of each group, from two separate experiments. Statistical analysis was
performed with ANOVA followed by Tukey’s multiple comparison post-hoc test. Significant differences between sample means are indicated
(#P ≤0.05; ##P ≤0.01; ###P ≤0.001 as compared to their respective sham; *P ≤0.05 and **P ≤0.01 compared to the PD-L1-/- mice post-MCAO). -/-,
knockout; ANOVA, analysis of variance; APC, antigen-presenting cell; MCAO, middle cerebral artery occlusion; PD-L1, programmed death-1 ligand
1; PD-L2, programmed death-1 ligand 2; PI, propidium iodide; SEM, standard error of the mean; WT, wild-type.
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characterized. This process depends in part on T cell ac-
tivation, in which the B7 family of co-stimulatory mole-
cules plays a pivotal role. T cells are localized in close
vicinity to blood vessels in the infarct boundary as early
as 24 hours after experimental focal cerebral ischemia in
rodents [8,35]. This early (24-hour) appearance of T cell
infiltration into the brain after MCAO [8,35] may indi-
cate that recruitment of activated cells is antigen-
nonspecific, perhaps generated by sympathetic signaling
from the brain to the periphery. Alternatively, leakage
of brain antigens across a compromised blood brain
barrier could initiate a peripheral immune response.
Activated T cells have the capacity to infiltrate the
brain, and could contribute to expansion of the ische-
mic penumbra, an area that already contains infiltrat-
ing neutrophils after 24 hours. In our previous
studies in severe combined immunodeficiency (SCID)
mice examining the hypothesis that activated periph-
eral T cells and B cells would home to the injured
brain and alter the evolving infarct, we found that
both cortical and total hemispheric infarct volumes
were strikingly reduced at 22 hours after MCAO [36],
thus indicating a damaging effect of T cells and B
cells on early evolving ischemic brain injury. However,
subsequent studies have convincingly demonstrated
the regulatory role played by the B cells in our model
of ischemic stroke [3,9]. Thus, this shifted the focus on
further discerning the role of pathogenic T cells. The out-
come of effector T cells is decided by the interaction of co-
stimulatory molecules on T cells and APCs. Studies in the
transient MCAO model [37] point to the non-essentiality
of the accessory TCR signaling via the PD-1/PD-L1 or
CD28-B7 pathway in early stroke progression. However,
since the end-point of these studies was as early as 22 hours
post-stroke, it was necessary to investigate the role of the
molecules that comprise the co-stimulatory pathway in T
cell activation beyond the 22-hour post-MCAO window.
Moreover, it is known that inflammation plays an import-
ant role in the pathogenesis of ischemic stroke, with stroke
patients with systemic inflammation exhibiting clinically
poorer outcomes [38,39]. Hence, in our earlier studies, we
determined the role of the receptor, PD-1, known to be a
part of a co-inhibitory pathway in T cell stimulation using
PD-1-/- mice which were subjected to 60 minutes of
MCAO followed by 96 hours of reperfusion. These studies
demonstrated a critical role for PD-1 in limiting functional
and histological damage after MCAO [7]. However the role
of the two PD-Ls was not known. Therefore, to complete
the picture, it was necessary to investigate the nature of in-
teractions between PD-1 and both its ligands for under-
standing the susceptibility, pathogenic mechanisms, and
protection afforded after ischemic stroke. Hence, the same
time point of reperfusion, as that followed for our earlier
studies in PD-1-/- mice, was selected as a starting point of
discerning the effects of interaction between PD-1 and its
ligands in ischemic stroke.
In our current study, we hypothesized a critical role
for the PD-Ls in exacerbating ischemic stroke. However,
as clearly demonstrated in Figures 1 and 2, the loss of
PD-L1 and to a lesser extent PD-L2 resulted in better
stroke outcomes and decreased infiltration of immune
cells in the ischemic hemisphere of PD-L1-/- mice. The
PD-1/PD-L pathway is recognized to control peripheral
T cell tolerance in several ways. This pathway can limit
the initial phase of activation and expansion of self-
reactive T cells, and restrict self-reactive T cell effector
function. The PD-1/PD-L interactions also play a role
in inhibiting expansion of naive self-reactive T cells
and/or their differentiation into effector T cells [11].
Thus, PD-L1 and PD-L2 can signal bidirectionally by
engaging PD-1 on T cells and by delivering signals
into PD-L-expressing cells. Although PD-L1 has been
consistently shown to be inhibitory in secondary phases of
immune reactions [40,41], its role in primary immune re-
actions is less clear. Initial reports have attributed both
stimulatory and inhibitory properties under conditions of
primary immune reactions [22]. However, a number of
recent studies suggest a ‘proautoimmune’ role for PD-L1
rather than a suppressive function. For example, trans-
genic over-expression of PD-L1 on pancreatic beta cells
enhanced autoimmunity instead of suppressing it [42]. As
a result of PD-L1 over-expression in beta cells, CD8+ T
cell proliferation was enhanced and immunological toler-
ance was broken, as mice developed spontaneous diabetes
[42]. In yet another study [43], an unexpected beneficial
effect from PD-L1-/- DCs was demonstrated where intra-
cerebral microinjections resulted in amelioration of subse-
quent experimental autoimmune encephalomyelitis (EAE)
[43]. Furthermore, this treatment was accompanied by
amplified neuroantigen-specific CD8+ Treg recruitment
into the CNS, suggesting that the lack of DC-derived PD-
L1 allows for the development (or recruitment) of regula-
tory CD8+ T cells (CD122+) in the CNS. Thus, by
‘inhibiting the inhibitors’, DC/APC expression of PD-L1 at
the site of inflammation leads to exacerbated autoimmun-
ity [44]. Our finding in this current study match this
aforementioned scenario, since as demonstrated in
Figure 5A,B, there was a loss of the suppressor CD8+
subpopulation from the periphery post-MCAO in the PD-
L1-/- mice, only to find its accumulation in the ischemic
half of the brains.
A number of lines of evidence have suggested a re-
ceptor for PD-L1 (B7-H1) or PD-L2 (B7-DC), aside
from PD-1. CD80 (B7-1) has recently been identified
as a binding partner for PD-L1 [11]. Surface plasmon
resonance studies demonstrate specific and unique inter-
action between PD-L1 and CD80, with an affinity (ap-
proximately 1.7 μM) intermediate between the affinities of
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CD80 for CD28 (4 μM) and CTLA-4 (0.2 μM), and PD-L1
for PD-1 (0.5 μM). CD86 (B7-2) does not bind to PD-L1
or PD-L2, and PD-L2 does not bind to CD80. CD80/
PD-L1 interactions can induce an inhibitory signal
into T cells. Ligation of PD-L1 on CD4 T cells by CD80,
or ligation of CD80 on CD4 T cells by PD-L1, delivers a
functionally significant inhibitory signal. CD80 acts specif-
ically through PD-L1 on the T cell in the absence of CD28
and CTLA-4. Thus, PD-L1 can exert an inhibitory effect
on T cells either through CD80 or PD-1. Because both
PD-L1 and CD80 are expressed on T cells, B cells, DCs,
and macrophages, there is the potential for bidirectional
interactions between CD80 and PD-L1 on these cell types.
In addition, PD-L1 on nonhematopoietic cells may inter-
act with CD80 as well as PD-1 on T cells to regulate cells.
In this scenario, PD-L1 binds CD80 to compete off CD28
binding due to its higher affinity interaction. Not mutually
exclusive, PD-L1 might also be required as a survival
signal for brain-derived CD8+ Tregs. Thus, as demon-
strated in Figure 6A,B,C in our present study, an increased
expression of CD80 on APCs in the WT and PD-L2-/-
mice might suggest an overriding CD80/CD28 interaction
leading to T cell activation. Conversely, low CD80 expres-
sion in PD-L1-/- mice and the increase in the total PD-L2
expression in the PD-L1-/- mice as compared to the WT
mice makes a plausible case for a PD-1/PD-L2 co-
inhibitory interaction in the absence of PD-L1.
However, one also needs to keep in mind that the broad
distribution of PD-L1 expression on hematopoietic and
parenchymal cells suggests one or both cell types may be
central to limiting autoimmune disease during multiple
phases of the immune responses. Due to its broad expres-
sion pattern in lymphoid and non-lymphoid organs, the
PD-L1/PD-1 pathway has been suggested to play a crucial
role for the maintenance of immune tolerance [45,46]. In
fact, the expression of PD-L1 on vascular endothelial cells
has led to the hypothesis that PD-L1 on endothelial cells
may regulate the activation of T cells that contact the ves-
sel wall, the extravasation of T cells into tissue, and/or
limit detrimental consequences of immunopathology [12].
Therefore, further studies pertaining to the role of PD-L1
on the endothelial cells become necessary in determining
the exact role of PD-L1 in ischemic stroke.
The present study has some limitations with regards
to outcome evaluations. First, we used a neurological
deficit scoring system to evaluate each animal. While
this scoring system is sensitive enough to confirm ische-
mia and consequent ischemic injury in each animal, it
may not be sensitive enough for evaluating subtle
changes in functional outcomes due to experimental ma-
nipulations or treatments. Future follow-up studies will
use more sophisticated and sensitive behavioral mea-
sures to evaluate functional outcomes at different time
points following ischemic insult in PD-L1-/-, PD-L2-/-,
and WT mice. Second, individuals performing infarct vol-
ume and immunological assessments were not blinded to
genotype. This potentially could have led to subjective bias
in assessing results. However, this seems unlikely given
that our observed results suggested a pathogenic rather
than the expected regulatory role for both PD-Ls. Lastly,
differences in striatal infarct volumes between PD-L1-/-
and PD-L2-/- mice could be due in part to altered glial
proliferative responses as suggested by earlier studies [47].
Evaluation of glial proliferation and the number of micro-
glia and astrocytes surrounding the infarct will be done in
future studies.
In summary, the current study conclusively demon-
strates for the first time that PD-L1-/- and PD-L2-/- mice
have smaller total infarct volume compared to WT mice.
Improved stroke outcome was accompanied by signifi-
cant reduction in the brain infiltrating cells as well as
their proinflammatory states in the PD-L1-/- and to a
lesser extent PD-L2-/- mice as compared to the WT
mice. Our study also demonstrated a novel connection
between the ischemic lesion in the brain and evolving
inflammatory changes in distant peripheral immune cell
populations. Reduction in infarct volumes promoted re-
duction in ischemia-related splenic atrophy accompanied
by lower activated states of the splenic T cells and
monocytes in the absence of the PD-L1, suggesting a
pathogenic rather than a regulatory role for both PD-Ls.
Suppressor T cells (IL-10-producing CD8+CD122+ T
cells) trafficked to the brain in PD-L1-/- mice and
their presence in the right MCAO-inflicted hemi-
sphere of the PD-L1-/- mice implicates them as pos-
sible key contributors in controlling further adverse
effects of ischemia. There was increased expression of
CD80 on splenic APCs in WT and PD-L2-/- mice,
suggesting an overriding interaction leading to T cell
activation. Conversely, low CD80 expression by the
APCs in PD-L1-/- mice suggests suppression possibly
via PD-1/PD-L2 interactions. Our novel observations
are the first to implicate PD-L1 in enhancing the se-
verity of experimental stroke. These results suggest
that agents (for example antibodies) that can target
and neutralize PD-L1/2 may have therapeutic poten-
tial for treatment of human stroke.
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